Gene
CRLF2
CRLF2 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (10), Actionable biomarkers (4), Trial mentions (18), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention CRLF2. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 with a planned future start.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 4 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 2 of 8,738 | 0.02% | not measured | |
| 2025 | 3 of 8,875 | 0.03% | not measured | |
| 2024 | 1 of 8,597 | 0.01% | not measured | |
| 2023 | 1 of 8,275 | 0.01% | 5 of 11,460 | 0.04% |
| 2022 | 1 of 8,285 | 0.01% | 11 of 13,598 | 0.08% |
| 2021 | 0 of 8,692 | 0.00% | 9 of 15,045 | 0.06% |
| 2020 | 0 of 7,640 | 0.00% | 6 of 14,459 | 0.04% |
| 2019 | 1 of 7,300 | 0.01% | 8 of 12,159 | 0.07% |
| 2018 | 1 of 6,927 | 0.01% | 7 of 11,854 | 0.06% |
| 2017 | 1 of 6,558 | 0.02% | 6 of 11,595 | 0.05% |
Showing 10 of 37 years.
Assay-provider ledger (10)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| AB Applied Biosystems | Reagent supplier | Clinical validation | 1 | September 13, 2016 |
| BD BioSciences | Reagent supplier | Clinical validation | 1 | September 13, 2016 |
| BECKMAN COULTER | Context dependent | Clinical validation | 1 | September 13, 2016 |
| BioLegend | Reagent supplier | Clinical validation | 1 | September 13, 2016 |
| Leibniz-Institute DSMZ - German Collection of Microorganisms and Cell Cultures | Not a company | Clinical validation | 1 | September 13, 2016 |
Showing 5 of 10 assay-provider companies.
Actionable biomarkers (4)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| CRLF2 fusion | Bet Inhibitors | response-associated | acute lymphoblastic leukemia | Cancer Genome Interpreter |
| CRLF2 fusion | Bet Inhibitors | response-associated | acute lymphoblastic leukemia | Cancer Genome Interpreter |
| CRLF2 fusion | Mtor Inhibitors | response-associated | acute lymphoblastic leukemia | Cancer Genome Interpreter |
| CRLF2 fusion | Mtor Inhibitors | response-associated | acute lymphoblastic leukemia | Cancer Genome Interpreter |
Trial mentions (18)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT06287229 | Trial eligibility (AACT) |
| NCT01164163 | Trial eligibility (AACT) |
| NCT07572136 | Trial eligibility (AACT) |
| NCT07359846 | Trial eligibility (AACT) |
| NCT05602194 | Trial eligibility (AACT) |
Showing 5 of 18 trial mentions.
Target-disease associations (340)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 22q11.2 deletion syndrome | cardiovascular disease | Mouse knockout (IMPC) |
| Adult-onset autosomal recessive sideroblastic anemia | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Alymphoid cystic thymic dysgenesis | immune system disease | Mouse knockout (IMPC) |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
Showing 5 of 340 associations.
Vendor sourcing (60)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| American Society of Hematology | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Subjects in CR must have a history of chemotherapy refractory disease defined as progression or stable disease after one line of chemotherapy, or relaps... | View trial NCT05507827 |
| American Society of Hematology | Trial collaborator | Mentioned in trial textTrial free-text mention | CRLF2 | View trial NCT05507827 |
| Autolus (United Kingdom) | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : I. Patients of age .18 years with high-risk B-cell ALL in first remission and \<5% BM blasts with at least one high-risk feature defined as: 1. Ph-negati... | View trial NCT07053059 |
| Autolus (United Kingdom) | Trial collaborator | Mentioned in trial textTrial free-text mention | CRLF2 | View trial NCT07053059 |
| Children's Oncology Group | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Eligible for study when participant is 1 year to 21 years at the time of diagnosis * Eligible Ages in Canada; 2 years to 21 years * De novo high-risk (H... | View trial NCT02723994 |
Showing 5 of 60 sourcing records.
Trial-cited literature (99)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Skin Tape Stripping Reveals Distinct Biomarker Profiles in Chronic Hand Eczema of Patients With and Without Comorbid Atopic Dermatitis. | Allergy | 2025 | 14 |
| A Phase I/II Trial of Ruxolitinib with Chemotherapy for Patients with Relapsed and/or Refractory Philadelphia-like Acute Lymphoblastic Leukemia. | Clinical lymphoma, myeloma & leukemia | 2025 | 8 |
| Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024 | 73 |
| Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024 | 25 |
| Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response. | Nature medicine | 2023 | 82 |
Showing 5 of 99 papers.
Protein variant mentions (3)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.F232C | 4 | 2012 to 2020 | PMID 33054110, PMID 23523389, PMID 22368272 |
| p.T46I | 1 | 2016 | PMID 27777593 |
| p.X210W | 1 | 2010 | PMID 20466416 |
Human sample screening reference (1)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.F232C | TARGET-ALL-P2 | Lymphoid Leukemias; Hematopoietic and reticuloendothelial systems | 7 | 768 | 0.91% | 0.44% to 1.87% |
Literature-extracted relations (25)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Chronic Disease | Disease | associate |
Skin Tape Stripping Reveals Distinct Biomarker Profiles in Chronic Hand Eczema of Patients With and Without Comorbid Atopic Dermatitis. | 2025 |
| Dermatitis, Atopic | Disease | associate |
Skin Tape Stripping Reveals Distinct Biomarker Profiles in Chronic Hand Eczema of Patients With and Without Comorbid Atopic Dermatitis. | 2025 |
| Eczema | Disease | associate |
Skin Tape Stripping Reveals Distinct Biomarker Profiles in Chronic Hand Eczema of Patients With and Without Comorbid Atopic Dermatitis. | 2025 |
| Inflammation | Disease | associate |
Skin Tape Stripping Reveals Distinct Biomarker Profiles in Chronic Hand Eczema of Patients With and Without Comorbid Atopic Dermatitis. | 2025 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | Disease | associate |
Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL. | 2024 |
Showing 5 of 25 relation assertions.
Organizations publishing (121)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Novant Health | Hospital | 20 | 2011 to 2024 |
| University of New Mexico | Academic | 8 | 2010 to 2024 |
| State University System of Florida | Academic | 7 | 2014 to 2024 |
| Government of the United States of America | Government | 6 | 2011 to 2022 |
| The University of Texas System | Academic | 5 | 2016 to 2024 |
Showing 5 of 121 organizations.
Where CRLF2 appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- integumentary system disease
- musculoskeletal or connective tissue disease
- nervous system disease
- phenotype
- respiratory or thoracic disease
281 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions and fda biomarker qualification projects.